Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Shiao, Rei-Tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S375000, C514S394000, C514S405000, C514S412000, C548S152000, C548S217000, C548S302700, C548S452000, C549S049000, C549S462000
Reexamination Certificate
active
07863305
ABSTRACT:
Compounds of formula I:or pharmaceutically acceptable salts, solvates or prodrugs thereof,wherein p, Ar, R1, R2, R3, Ra, Rb, Rc, Rdand Reare defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
REFERENCES:
patent: 2708197 (1955-05-01), Speeter
patent: 2752358 (1956-06-01), Ehrhart et al.
patent: 2984670 (1961-05-01), Szmuszkovicz et al.
patent: 2005/0222148 (2005-10-01), Kim et al.
patent: 2006/0025467 (2006-02-01), Greenhouse et al.
patent: 849 108 (1952-09-01), None
patent: 0 509 402 (1992-10-01), None
patent: 0 534 343 (1993-03-01), None
patent: 0 600 830 (1993-11-01), None
patent: 0 775 694 (1997-05-01), None
patent: 0 887 348 (1998-12-01), None
patent: 2 814 073 (2002-03-01), None
patent: 705652 (1954-03-01), None
patent: 992731 (1965-05-01), None
patent: 3-14562 (1991-01-01), None
patent: WO 94/12478 (1994-06-01), None
patent: WO 96-40094 (1996-12-01), None
patent: WO 97/10219 (1997-03-01), None
patent: WO 97/46511 (1997-12-01), None
patent: WO 98/43942 (1998-10-01), None
patent: WO 99/16755 (1999-04-01), None
patent: WO 99/21553 (1999-05-01), None
patent: WO 99/21557 (1999-05-01), None
patent: WO 00/02551 (2000-01-01), None
patent: WO 01/32622 (2001-05-01), None
patent: WO 02/069965 (2002-09-01), None
CAPLUS Accession No. 1955:24163, abstract of GB 705652.
Caplus Accession No. 1955:24163, abstract of GB 705652.
Ganellin, C.R., et al., “Aminoalkylation of Metal Derivatives of Indole: Part III.” J. Chem Society, Section C (Organic), vol. 11, 1969, pp. 1537-1540.
Lindner, E., “Über ein neues Antihistaminicum, das-1-Phenyl-1-Pyridy1-(2)-3-dimethylaminopropan und sein Salz mit der p-Aminosalicylsäure (A vil)”, Naunyn-Schmiedbergs Archiv für Pharmakologie und Experimentelle Pathologie, vol. 211, 1950, pp. 328-344.
Kraxner, J. et. al., “Azepino- and Diazepinoindoles: Synthesis and Dopamine Receptor Binding Profiles,”Archiv der Pharmazie, vol. 333 (9) 2000 pp. 287-292.
Schmidt, A. M. et. al., “Synthesis of Pharmacologically Relevant Indoles with Amine Side Chains via Tandem Hydroformylation/Fischer Indole Synthesis,”J. Organic Chem. vol. 70 (14) 2005 pp. 5528-5535.
Greenhouse Robert
Jaime-Figueroa Saul
Raptova Lubica
Reuter Deborah Carol
Stein Karin Ann
Coppins Janet L
Hall Robert C.
Roche Palo Alto LLC
Shiao Rei-tsang
LandOfFree
3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2670981